LT4477B - Fluoksetino enterinės piliulės - Google Patents

Fluoksetino enterinės piliulės Download PDF

Info

Publication number: LT4477B
Authority: LT; Lithuania
Prior art keywords: fluoxetine; layer; enteric; core; hpmcas
Prior art date: 1997-05-29

Application number

LT98-058A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT98058A (en

Inventor

Neil Robert Anderson

Roger Garrick Harrison

Daniel Frederick Lynch

Peter Lloyd Oren

Original Assignee

Eli Lilly And Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-29

Filing date

1998-04-22

Publication date

1999-03-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25349313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4477(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-04-22 Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company

1998-10-26 Publication of LT98058A publication Critical patent/LT98058A/xx

1999-03-25 Publication of LT4477B publication Critical patent/LT4477B/lt

Links

229960002464 fluoxetine Drugs 0.000 claims abstract description 92
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims abstract description 90
239000012055 enteric layer Substances 0.000 claims abstract description 25
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims abstract description 23
239000000203 mixture Substances 0.000 claims abstract description 18
238000009472 formulation Methods 0.000 claims abstract description 12
239000008188 pellet Substances 0.000 claims abstract description 10
239000000935 antidepressant agent Substances 0.000 claims abstract description 6
239000010410 layer Substances 0.000 claims description 62
239000006187 pill Substances 0.000 claims description 42
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 29
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 25
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 23
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 23
235000000346 sugar Nutrition 0.000 claims description 23
239000000454 talc Substances 0.000 claims description 22
229910052623 talc Inorganic materials 0.000 claims description 22
238000000034 method Methods 0.000 claims description 20
229930006000 Sucrose Natural products 0.000 claims description 19
ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 19
239000005720 sucrose Substances 0.000 claims description 19
239000002552 dosage form Substances 0.000 claims description 18
239000002245 particle Substances 0.000 claims description 18
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 17
229940023488 pill Drugs 0.000 claims description 16
239000000546 pharmaceutical excipient Substances 0.000 claims description 15
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 14
238000004519 manufacturing process Methods 0.000 claims description 12
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 claims description 10
229960000389 fluoxetine hydrochloride Drugs 0.000 claims description 10
206010036618 Premenstrual syndrome Diseases 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
230000008569 process Effects 0.000 claims description 8
229920002472 Starch Polymers 0.000 claims description 7
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 7
208000035475 disorder Diseases 0.000 claims description 7
239000008107 starch Substances 0.000 claims description 7
239000004408 titanium dioxide Substances 0.000 claims description 7
239000001069 triethyl citrate Substances 0.000 claims description 7
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 7
235000013769 triethyl citrate Nutrition 0.000 claims description 7
208000027559 Appetite disease Diseases 0.000 claims description 6
208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
239000007900 aqueous suspension Substances 0.000 claims description 6
238000004040 coloring Methods 0.000 claims description 6
208000032841 Bulimia Diseases 0.000 claims description 5
206010006550 Bulimia nervosa Diseases 0.000 claims description 5
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 5
229910021529 ammonia Inorganic materials 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 5
230000036651 mood Effects 0.000 claims description 5
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 4
208000019901 Anxiety disease Diseases 0.000 claims description 4
208000019022 Mood disease Diseases 0.000 claims description 4
230000001430 anti-depressive effect Effects 0.000 claims description 4
229940005513 antidepressants Drugs 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 4
239000007903 gelatin capsule Substances 0.000 claims description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
229960002715 nicotine Drugs 0.000 claims description 4
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 4
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 3
239000000908 ammonium hydroxide Substances 0.000 claims description 3
150000001720 carbohydrates Chemical class 0.000 claims description 3
235000014633 carbohydrates Nutrition 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 3
229960002508 pindolol Drugs 0.000 claims description 3
208000008811 Agoraphobia Diseases 0.000 claims description 2
208000007848 Alcoholism Diseases 0.000 claims description 2
208000024827 Alzheimer disease Diseases 0.000 claims description 2
208000000044 Amnesia Diseases 0.000 claims description 2
208000031091 Amnestic disease Diseases 0.000 claims description 2
208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
201000001320 Atherosclerosis Diseases 0.000 claims description 2
208000017164 Chronobiology disease Diseases 0.000 claims description 2
206010013954 Dysphoria Diseases 0.000 claims description 2
206010020772 Hypertension Diseases 0.000 claims description 2
201000001916 Hypochondriasis Diseases 0.000 claims description 2
208000002193 Pain Diseases 0.000 claims description 2
206010037180 Psychiatric symptoms Diseases 0.000 claims description 2
206010041250 Social phobia Diseases 0.000 claims description 2
230000001154 acute effect Effects 0.000 claims description 2
206010001584 alcohol abuse Diseases 0.000 claims description 2
208000025746 alcohol use disease Diseases 0.000 claims description 2
230000006986 amnesia Effects 0.000 claims description 2
208000030963 borderline personality disease Diseases 0.000 claims description 2
229960004126 codeine Drugs 0.000 claims description 2
XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims description 2
229960004193 dextropropoxyphene Drugs 0.000 claims description 2
206010016256 fatigue Diseases 0.000 claims description 2
229940064371 fluoxetine pill Drugs 0.000 claims description 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 2
230000006993 memory improvement Effects 0.000 claims description 2
230000003340 mental effect Effects 0.000 claims description 2
229960005181 morphine Drugs 0.000 claims description 2
206010036596 premature ejaculation Diseases 0.000 claims description 2
201000000980 schizophrenia Diseases 0.000 claims description 2
230000035945 sensitivity Effects 0.000 claims description 2
208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
208000015891 sexual disease Diseases 0.000 claims description 2
208000019116 sleep disease Diseases 0.000 claims description 2
230000005586 smoking cessation Effects 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
230000004580 weight loss Effects 0.000 claims description 2
208000016261 weight loss Diseases 0.000 claims description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 4
239000001384 succinic acid Substances 0.000 claims 2
125000000185 sucrose group Chemical group 0.000 claims 2
206010012374 Depressed mood Diseases 0.000 claims 1
208000003028 Stuttering Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
208000024891 symptom Diseases 0.000 claims 1
230000000472 traumatic effect Effects 0.000 claims 1
229920000642 polymer Polymers 0.000 description 40
239000000725 suspension Substances 0.000 description 24
239000000047 product Substances 0.000 description 23
235000012222 talc Nutrition 0.000 description 20
238000000576 coating method Methods 0.000 description 16
239000000463 material Substances 0.000 description 13
239000002585 base Substances 0.000 description 12
239000011248 coating agent Substances 0.000 description 12
239000000843 powder Substances 0.000 description 12
239000002775 capsule Substances 0.000 description 11
239000000945 filler Substances 0.000 description 9
238000006386 neutralization reaction Methods 0.000 description 9
239000002002 slurry Substances 0.000 description 9
239000003826 tablet Substances 0.000 description 9
238000009505 enteric coating Methods 0.000 description 8
239000002702 enteric coating Substances 0.000 description 8
239000004615 ingredient Substances 0.000 description 8
150000001875 compounds Chemical class 0.000 description 7
239000012530 fluid Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
239000000853 adhesive Substances 0.000 description 6
238000001035 drying Methods 0.000 description 6
238000005507 spraying Methods 0.000 description 6
230000001070 adhesive effect Effects 0.000 description 5
239000011230 binding agent Substances 0.000 description 5
239000007921 spray Substances 0.000 description 5
230000003068 static effect Effects 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
239000004480 active ingredient Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000012467 final product Substances 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
208000024714 major depressive disease Diseases 0.000 description 4
239000004014 plasticizer Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 3
-1 60-120 mg) Chemical compound 0.000 description 3
208000020401 Depressive disease Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000012792 core layer Substances 0.000 description 3
230000002354 daily effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
229960002866 duloxetine Drugs 0.000 description 3
239000010419 fine particle Substances 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000009115 maintenance therapy Methods 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
238000005054 agglomeration Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
239000002518 antifoaming agent Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000011247 coating layer Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000006870 function Effects 0.000 description 2
238000000227 grinding Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
230000003993 interaction Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000008023 pharmaceutical filler Substances 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
239000012453 solvate Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
239000001993 wax Substances 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000167880 Hirundinidae Species 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
206010048010 Withdrawal syndrome Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000012790 adhesive layer Substances 0.000 description 1
208000012826 adjustment disease Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
208000025748 atypical depressive disease Diseases 0.000 description 1
239000011324 bead Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000007771 core particle Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
229960003914 desipramine Drugs 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
WMVRXDZNYVJBAH-UHFFFAOYSA-N dioxoiron Chemical compound O=[Fe]=O WMVRXDZNYVJBAH-UHFFFAOYSA-N 0.000 description 1
LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000007919 dispersible tablet Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000000428 dust Substances 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
201000003104 endogenous depression Diseases 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000012458 free base Chemical group 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000009499 grossing Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000155 melt Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
SYJIMQIHZKHRQC-UHFFFAOYSA-N n-methyl-3-(3-naphthalen-1-yloxythiophen-2-yl)propan-1-amine Chemical compound S1C=CC(OC=2C3=CC=CC=C3C=CC=2)=C1CCCNC SYJIMQIHZKHRQC-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
208000015238 neurotic disease Diseases 0.000 description 1
229960001158 nortriptyline Drugs 0.000 description 1
239000003605 opacifier Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000003825 pressing Methods 0.000 description 1
238000005086 pumping Methods 0.000 description 1
229920013730 reactive polymer Polymers 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
229960004029 silicic acid Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229940033134 talc Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000003245 working effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

LT98-058A 1997-05-29 1998-04-22 Fluoksetino enterinės piliulės LT4477B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/867,196 US5910319A (en)	1997-05-29	1997-05-29	Fluoxetine enteric pellets and methods for their preparation and use

Publications (2)

Publication Number	Publication Date
LT98058A LT98058A (en)	1998-10-26
LT4477B true LT4477B (lt)	1999-03-25

Family

ID=25349313

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT98-058A LT4477B (lt)	1997-05-29	1998-04-22	Fluoksetino enterinės piliulės

Country Status (45)

Country	Link
US (3)	US5910319A (es)
JP (1)	JP3210288B2 (es)
KR (1)	KR100549473B1 (es)
CN (2)	CN1161109C (es)
AR (1)	AR011728A1 (es)
AT (1)	AT408068B (es)
AU (1)	AU726690B2 (es)
BE (1)	BE1011925A3 (es)
BR (1)	BR9801989A (es)
CA (1)	CA2234826C (es)
CH (1)	CH693018A5 (es)
CO (1)	CO4940407A1 (es)
CZ (1)	CZ290582B6 (es)
DE (1)	DE19823940B4 (es)
DK (1)	DK176776B1 (es)
ES (1)	ES2161574B1 (es)
FI (1)	FI119971B (es)
FR (1)	FR2763846B1 (es)
GB (1)	GB2325623B (es)
GR (1)	GR980100188A (es)
HU (1)	HUP9800882A3 (es)
ID (1)	ID20343A (es)
IL (1)	IL124073A (es)
IT (1)	ITMI980908A1 (es)
LT (1)	LT4477B (es)
LU (1)	LU90245B1 (es)
LV (1)	LV12176B (es)
MY (1)	MY118139A (es)
NL (1)	NL1009259C2 (es)
NO (1)	NO317743B1 (es)
NZ (1)	NZ330192A (es)
PE (1)	PE75399A1 (es)
PL (1)	PL192293B1 (es)
PT (1)	PT102152B (es)
RO (1)	RO120043B1 (es)
RS (1)	RS49827B (es)
RU (1)	RU2164405C2 (es)
SE (1)	SE522914C2 (es)
SG (1)	SG72805A1 (es)
SI (1)	SI9800128B (es)
SV (1)	SV1998000052A (es)
TR (1)	TR199800937A2 (es)
TW (1)	TWI239838B (es)
UA (1)	UA48193C2 (es)
ZA (1)	ZA983173B (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2752732B1 (fr) *	1996-08-28	1998-11-20	Pf Medicament	Forme galenique a liberation prolongee de milnacipran
IE990406A1 (en)	1999-05-20	2000-12-27	Elan Corp Plc	Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
CA2374039C (en) *	1999-05-20	2011-01-11	Elan Corporation Plc	Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
ES2162560B1 (es) *	1999-06-25	2002-07-16	Rodriguez Concepcion Pena	Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
DK1225881T3 (da)	1999-09-03	2006-06-12	Apbi Holdings Llc	Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion
CN1094347C (zh) *	1999-11-15	2002-11-20	广东药学院药物研究所	一种治疗前列腺良性增生症的控释微丸及其制备方法
US6273260B1 (en)	2000-03-08	2001-08-14	Eli Lilly And Company	Pharmaceutical packaging system
ES2185452B2 (es) *	2000-08-01	2004-03-16	Cinfa S A Lab	Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion.
JP4181738B2 (ja) *	2000-08-25	2008-11-19	信越化学工業株式会社	腸溶性コーティング製剤の製造方法
US6482440B2 (en) *	2000-09-21	2002-11-19	Phase 2 Discovery, Inc.	Long acting antidepressant microparticles
WO2002038126A2 (en) *	2000-11-08	2002-05-16	Aeromatic-Fielder Ag	A process for production of particles for pharmaceutical compositions having increased bioavailability
US20040170688A1 (en) *	2001-08-06	2004-09-02	Deshmukh Abhijit Mukund	Enteric formulation of fluoxetin
CA2457385A1 (en)	2001-08-06	2003-02-20	Dr. Reddy's Laboratories Ltd.	Improved enteric formulation of fluoxetin
US20040220153A1 (en) *	2002-09-24	2004-11-04	Jost-Price Edward Roydon	Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2002361495A1 (en) *	2002-12-24	2004-07-22	Lupin Limited	Enteric coated fluoxetine composition
US8614247B2 (en) *	2003-04-10	2013-12-24	Institut National De La Sante Et De La Recherche Medicale	Methods for preventing, attenuating or treating pulmonary hypertension using a serotonin transporter inhibitor, and pharmaceutical compositions for the treatment thereof
CA2526730A1 (en)	2003-05-30	2004-12-09	Ranbaxy Laboratories Limited	Substituted pyrrole derivatives
US20050176693A1 (en) *	2003-08-12	2005-08-11	Boissonneault Roger M.	Method of intermittent administration of a pharmaceutical for the treatment of conditions associated with a female's menstrual cycle
WO2005065726A1 (en) *	2003-12-30	2005-07-21	Dr. Reddy's Laboratories Ltd.	Pharmaceutical composition
CA2579767A1 (en) *	2004-04-30	2005-11-10	Astellas Pharma Inc.	Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
KR100920856B1 (ko) *	2004-11-30	2009-10-09	(주)아모레퍼시픽	선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
JP2007523213A (ja) *	2004-12-23	2007-08-16	テバファーマシューティカルインダストリーズリミティド	医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
JP5153629B2 (ja) *	2005-08-02	2013-02-27	ルピン・リミテッド	選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
JP2009514851A (ja)	2005-11-08	2009-04-09	ランバクシーラボラトリーズリミテッド	（３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
WO2007062119A1 (en) *	2005-11-23	2007-05-31	Auspex Pharmaceuticals, Inc.	Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
WO2007067581A1 (en) *	2005-12-05	2007-06-14	Teva Pharmaceutical Industries Ltd.	2-(n-methyl-propanamine)-3-(2-naphthol) thiophene, an impurity of duloxetine hydrochloride
US20080033030A1 (en) *	2006-02-24	2008-02-07	Capua Simona D	Fluvastatin sodium pharmaceutical compositions
CN101057837B (zh) *	2006-04-20	2010-12-22	湖南九典制药有限公司	一种右旋酮洛芬肠溶微丸及制备方法
EP2016066A4 (en) *	2006-05-10	2010-11-24	Reddys Lab Ltd Dr	PROCESS FOR PREPARING DULOXETINE
JP2009538315A (ja) *	2006-05-22	2009-11-05	テバファーマシューティカルインダストリーズリミティド	塩酸デュロキセチン遅延放出型製剤
US20100297226A1 (en) *	2006-06-01	2010-11-25	Dexcel Pharma Technologies Ltd.	Multiple unit pharmaceutical formulation
JP5052051B2 (ja) *	2006-06-16	2012-10-17	トーアエイヨー株式会社	腸溶性顆粒剤及びその製造方法
US20090252787A1 (en) *	2006-07-28	2009-10-08	Dr. Reddy's Laboratories Ltd.	Granular pharmaceutical compositions
US20080033050A1 (en)	2006-08-04	2008-02-07	Richards Patricia Allison Tewe	Method of treating thermoregulatory disfunction with paroxetine
WO2008020286A2 (en) *	2006-08-14	2008-02-21	Torrent Pharmaceuticals Limited	Pharmaceutical compositions of duloxetine
CA2664421A1 (en) *	2006-09-22	2008-03-27	Braincells, Inc.	Hmg coa reductase mediated modulation of neurogenesis
US20080226711A1 (en) *	2007-03-12	2008-09-18	Torrent Pharmaceuticals Ltd.	Pharmaceutical compositions of duloxetine
US20090226517A1 (en) *	2008-02-06	2009-09-10	Vinita Umashankar Vyas	Pharmaceutical formulations comprising duloxetine
MY156288A (en)	2008-07-16	2016-01-29	Richter Gedeon Nyrt	Pharmaceutical formulations containing dopamine receptor ligands.
WO2010026993A1 (ja) *	2008-09-03	2010-03-11	武田薬品工業株式会社	製剤における吸収性改善方法および吸収性が改善された製剤
CN101804145B (zh) *	2009-02-12	2012-11-14	杭州赛利药物研究所有限公司	一种大蒜油肠溶微丸胶囊及其制备方法
JP2013504562A (ja) *	2009-09-17	2013-02-07	カディラ・ヘルスケア・リミテッド	アルコールで誘発される用量ダンピングを低減するための医薬組成物
JP5749247B2 (ja) *	2010-02-22	2015-07-15	第一三共株式会社	経口用徐放性固形製剤
RU2442572C1 (ru) *	2010-12-23	2012-02-20	Ольга Львовна Титова	Энтеросолюбильная оболочка и композиция для ее получения
CA2870134C (en) *	2012-05-02	2020-04-28	Capsugel France SAS	Aqueous dispersions of hydroxypropyl methylcellulose acetate succinate (hpmcas)
CN102716084B (zh) *	2012-06-29	2013-09-25	海南美大制药有限公司	盐酸氟西汀脂质体固体制剂
JP6129184B2 (ja)	2012-09-03	2017-05-17	第一三共株式会社	ヒドロモルフォン塩酸塩含有の経口用徐放性医薬組成物
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
KR20170005833A (ko)	2014-05-20	2017-01-16	다우 글로벌 테크놀로지스 엘엘씨	부분적으로 중화된 에스테르화 셀룰로오스 에테르를 포함하는 분산물
WO2015179073A1 (en) *	2014-05-20	2015-11-26	Dow Global Technologies Llc	Capsule shells comprising an esterified cellulose ether
WO2015187874A1 (en) *	2014-06-07	2015-12-10	Structure-Ase, Inc.	A method for the detection and/or diagnosis of eating disorders and malnutrition using x-ray diffraction
US10471152B2 (en)	2014-08-29	2019-11-12	Capsugel Belgium Nv	Colloidal dispersion comprising HPMCAS
EP3288556A4 (en)	2015-04-29	2018-09-19	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
US11274087B2 (en)	2016-07-08	2022-03-15	Richter Gedeon Nyrt.	Industrial process for the preparation of cariprazine
EP3609578A4 (en) *	2017-04-13	2021-03-10	Chase Therapeutics Corporation	PHARMACEUTICAL COMBINATION AND ITS USE FOR THE TREATMENT OF SYNUCLEINOPATHIES
HUP1700253A1 (hu)	2017-06-13	2019-01-28	Richter Gedeon Nyrt	Szilárd orális gyógyszerkészítmények
CN107898942B (zh) *	2017-11-24	2021-01-26	一力制药(罗定)有限公司	一种感冒清热胶囊及其制备方法
US11547707B2 (en)	2019-04-10	2023-01-10	Richter Gedeon Nyrt.	Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
JP7606825B2 (ja) *	2020-06-15	2024-12-26	東和薬品株式会社	エソメプラゾール顆粒ならびにその製造方法および用途
WO2022115054A1 (en) *	2020-11-27	2022-06-02	Santa Farma Ilac Sanayii A.S.	Enteric coated duloxetine compositions

Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4314081A (en)	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
US4444778A (en)	1981-08-27	1984-04-24	Coughlin Shaun R	Method and composition for treating atherosclerosis
US4626549A (en)	1974-01-10	1986-12-02	Eli Lilly And Company	Treatment of obesity with aryloxyphenylpropylamines
US4847092A (en)	1985-11-12	1989-07-11	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulations
US5104899A (en)	1990-08-13	1992-04-14	Sepracor, Inc.	Methods and compositions for treating depression using optically pure fluoxetine
WO1992013452A1 (en)	1991-02-04	1992-08-20	Young James W	Methods of use and compositions of r(-) fluoxetine
US5356934A (en)	1990-03-29	1994-10-18	Eli Lilly And Company	Selected serotonin subtype receptor agonist to treat sleep apnea
EP0693281A2 (en)	1994-07-20	1996-01-24	Lilly S.A.	Fluoxetine Pharmaceutical formulations
US5508276A (en)	1994-07-18	1996-04-16	Eli Lilly And Company	Duloxetine enteric pellets

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4194009A (en)	1974-01-10	1980-03-18	Eli Lilly And Company	Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4018895A (en)	1974-01-10	1977-04-19	Eli Lilly And Company	Aryloxyphenylpropylamines in treating depression
JPS517116A (en)	1974-06-11	1976-01-21	Shinetsu Chemical Co	Choyoseihifukuyakuzaino seizohoho
CH649216A5 (de)	1979-08-16	1985-05-15	Sandoz Ag	Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
JPS5855125B2 (ja) *	1980-03-10	1983-12-08	信越化学工業株式会社	固形薬剤用腸溶性コ−テイング剤組成物
US4797286A (en)	1985-11-12	1989-01-10	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulations
GB2189699A (en)	1986-04-30	1987-11-04	Haessle Ab	Coated acid-labile medicaments
US4918242A (en)	1988-03-30	1990-04-17	Aldrich Chemical Company, Inc.	Novel optically 1,3-phenoxypropylhalides
CA1337955C (en) *	1988-09-26	1996-01-23	Thomas A. Almquist	Recoating of stereolithographic layers
US4999382A (en) *	1988-10-26	1991-03-12	Massachusetts Institute Of Technology	Compositions for treating tobacco withdrawal symptoms and methods for their use
US5589511A (en) *	1990-08-13	1996-12-31	Sepracor Inc.	Method for treating migraine headaches using optically pure S(+) fluoxetine
JPH04202124A (ja) *	1990-11-29	1992-07-22	Fuji Kagaku Kogyo Kk	噴霧乾燥造粒法による薬物放出の制御された製剤の製造法
CA2102507A1 (en) *	1991-05-07	1992-11-08	Judith P. Kitchell	A controlled, sustained release delivery system for smoking cessation
AU668386B2 (en) *	1992-03-25	1996-05-02	Depomed Systems, Incorporated	Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5518730A (en) *	1992-06-03	1996-05-21	Fuisz Technologies Ltd.	Biodegradable controlled release flash flow melt-spun delivery system
JPH06293633A (ja) *	1993-04-05	1994-10-21	Shin Etsu Chem Co Ltd	水性腸溶性エマルジョンの製造方法
US5362886A (en)	1993-10-12	1994-11-08	Eli Lilly And Company	Asymmetric synthesis
DK0726761T3 (da) *	1993-11-03	2001-06-18	Isomed Inc	Mikropartikulære farmaceutiske præparater på micel-form
CA2134038C (en) *	1994-06-16	1997-06-03	David Taiwai Wong	Potentiation of drug response
JPH08109126A (ja) *	1994-10-07	1996-04-30	Amano Pharmaceut Co Ltd	耐衝撃性腸溶性顆粒剤およびこれを含有する錠剤
JPH08245423A (ja) *	1995-03-06	1996-09-24	Shionogi & Co Ltd	水系腸溶性コーティング液
GB9514842D0 (en) *	1995-07-20	1995-09-20	Smithkline Beecham Plc	Novel formulation

1997
- 1997-05-29 US US08/867,196 patent/US5910319A/en not_active Ceased
1998
- 1998-04-13 IL IL12407398A patent/IL124073A/en not_active IP Right Cessation
- 1998-04-14 RO RO98-00869A patent/RO120043B1/ro unknown
- 1998-04-14 RU RU98106998/14A patent/RU2164405C2/ru active
- 1998-04-14 CA CA002234826A patent/CA2234826C/en not_active Expired - Lifetime
- 1998-04-15 GB GB9807939A patent/GB2325623B/en not_active Expired - Lifetime
- 1998-04-15 UA UA98041929A patent/UA48193C2/uk unknown
- 1998-04-15 ZA ZA9803173A patent/ZA983173B/xx unknown
- 1998-04-15 NZ NZ330192A patent/NZ330192A/xx not_active IP Right Cessation
- 1998-04-15 HU HU9800882A patent/HUP9800882A3/hu not_active Application Discontinuation
- 1998-04-15 CZ CZ19981143A patent/CZ290582B6/cs not_active IP Right Cessation
- 1998-04-15 RS YUP-165/98A patent/RS49827B/sr unknown
- 1998-04-16 MY MYPI98001702A patent/MY118139A/en unknown
- 1998-04-16 FI FI980846A patent/FI119971B/fi active IP Right Grant
- 1998-04-17 SG SG1998000871A patent/SG72805A1/en unknown
- 1998-04-17 SE SE9801336A patent/SE522914C2/sv not_active IP Right Cessation
- 1998-04-20 KR KR1019980014014A patent/KR100549473B1/ko not_active Expired - Lifetime
- 1998-04-22 LT LT98-058A patent/LT4477B/lt not_active IP Right Cessation
- 1998-04-24 CN CNB981087787A patent/CN1161109C/zh not_active Expired - Lifetime
- 1998-04-24 JP JP15350198A patent/JP3210288B2/ja not_active Expired - Lifetime
- 1998-04-28 IT IT98MI000908A patent/ITMI980908A1/it unknown
- 1998-04-28 SV SV1998000052A patent/SV1998000052A/es unknown
- 1998-04-28 ES ES009800899A patent/ES2161574B1/es not_active Expired - Fee Related
- 1998-04-29 SI SI9800128A patent/SI9800128B/sl unknown
- 1998-05-01 PL PL326134A patent/PL192293B1/pl unknown
- 1998-05-07 AR ARP980102130A patent/AR011728A1/es not_active Application Discontinuation
- 1998-05-08 PT PT102152A patent/PT102152B/pt active IP Right Grant
- 1998-05-11 TW TW087107241A patent/TWI239838B/zh not_active IP Right Cessation
- 1998-05-12 CO CO98026349A patent/CO4940407A1/es unknown
- 1998-05-13 FR FR9806040A patent/FR2763846B1/fr not_active Expired - Lifetime
- 1998-05-14 NO NO19982197A patent/NO317743B1/no not_active IP Right Cessation
- 1998-05-19 BR BR9801989-9A patent/BR9801989A/pt not_active Application Discontinuation
- 1998-05-20 BE BE9800383A patent/BE1011925A3/fr not_active IP Right Cessation
- 1998-05-20 LU LU90245A patent/LU90245B1/fr active
- 1998-05-25 LV LVP-98-121A patent/LV12176B/xx unknown
- 1998-05-26 CH CH01157/98A patent/CH693018A5/de not_active IP Right Cessation
- 1998-05-26 NL NL1009259A patent/NL1009259C2/nl not_active IP Right Cessation
- 1998-05-27 TR TR1998/00937A patent/TR199800937A2/xx unknown
- 1998-05-28 DE DE19823940A patent/DE19823940B4/de not_active Expired - Lifetime
- 1998-05-28 GR GR980100188A patent/GR980100188A/el unknown
- 1998-05-28 ID IDP980791A patent/ID20343A/id unknown
- 1998-05-28 AU AU69048/98A patent/AU726690B2/en not_active Expired
- 1998-05-28 PE PE1998000430A patent/PE75399A1/es not_active Application Discontinuation
- 1998-05-28 DK DK199800728A patent/DK176776B1/da not_active IP Right Cessation
- 1998-05-29 AT AT0093198A patent/AT408068B/de not_active IP Right Cessation
1999
- 1999-03-10 US US09/265,610 patent/US5985322A/en not_active Expired - Lifetime
2000
- 2000-07-25 CN CNB001222090A patent/CN1212834C/zh not_active Expired - Lifetime
2002
- 2002-01-28 US US10/058,891 patent/USRE39030E1/en not_active Expired - Lifetime

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4314081A (en)	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
US4626549A (en)	1974-01-10	1986-12-02	Eli Lilly And Company	Treatment of obesity with aryloxyphenylpropylamines
US4444778A (en)	1981-08-27	1984-04-24	Coughlin Shaun R	Method and composition for treating atherosclerosis
US4847092A (en)	1985-11-12	1989-07-11	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulations
US5356934A (en)	1990-03-29	1994-10-18	Eli Lilly And Company	Selected serotonin subtype receptor agonist to treat sleep apnea
US5104899A (en)	1990-08-13	1992-04-14	Sepracor, Inc.	Methods and compositions for treating depression using optically pure fluoxetine
WO1992013452A1 (en)	1991-02-04	1992-08-20	Young James W	Methods of use and compositions of r(-) fluoxetine
US5508276A (en)	1994-07-18	1996-04-16	Eli Lilly And Company	Duloxetine enteric pellets
EP0693281A2 (en)	1994-07-20	1996-01-24	Lilly S.A.	Fluoxetine Pharmaceutical formulations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BENAZZI F, MAZZOLI M.: "Fluoxetine-induced sexual dysfunction: a dose-dependent effect?", PHARMACOPSYCHIATRY, 1994, pages 246
BURKE ET AL.: "Weekly Fluoxetine Controls Symptoms of Depression", PSYCHOPHARMACOLOGY BULLETIN, 1995, pages 524
MONTGOMERY D B ET AL.: "Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts", EUR ARCH PSYCHIATRY CLIN NEUROSCI, 1994, pages 211
ROBERTSON DW ET AL.: "Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor", J MED CHEM., 1988, pages 1412, XP000568845, DOI: doi:10.1021/jm00402a027

Also Published As

Publication number	Publication date
DE19823940A1 (de)	1998-12-03
LT98058A (en)	1998-10-26
LU90245B1 (fr)	2002-07-31
CN1212834C (zh)	2005-08-03
FI119971B (fi)	2009-05-29
NL1009259C2 (nl)	1998-12-01
AT408068B (de)	2001-08-27
RS49827B (sr)	2008-08-07
FR2763846B1 (fr)	2001-05-18
CZ114398A3 (cs)	1998-12-16
ES2161574A1 (es)	2001-12-01
AR011728A1 (es)	2000-08-30
GB2325623B (en)	1999-04-14
SI9800128A (sl)	1999-02-28
PT102152A (pt)	1998-12-31
DK176776B1 (da)	2009-08-10
RO120043B1 (ro)	2005-08-30
IE980284A1 (en)	2000-07-12
CO4940407A1 (es)	2000-07-24
PL192293B1 (pl)	2006-09-29
CA2234826A1 (en)	1998-11-29
JPH10330253A (ja)	1998-12-15
SE9801336D0 (sv)	1998-04-17
UA48193C2 (uk)	2002-08-15
SE9801336L (sv)	1998-11-30
CA2234826C (en)	2000-12-19
USRE39030E1 (en)	2006-03-21
SI9800128B (sl)	2000-04-30
PT102152B (pt)	2000-09-29
LV12176A (lv)	1998-12-20
YU16598A (en)	1999-11-22
HUP9800882A3 (en)	2000-07-28
ATA93198A (de)	2001-01-15
US5985322A (en)	1999-11-16
PE75399A1 (es)	1999-08-17
NO982197L (no)	1998-11-30
DE19823940B4 (de)	2010-04-29
FI980846L (fi)	1998-11-30
ES2161574B1 (es)	2002-06-16
NO317743B1 (no)	2004-12-13
GB2325623A (en)	1998-12-02
FI980846A0 (fi)	1998-04-16
CZ290582B6 (cs)	2002-08-14
HUP9800882A2 (hu)	2000-03-28
GB9807939D0 (en)	1998-06-10
CN1200924A (zh)	1998-12-09
TR199800937A3 (tr)	1999-10-21
CN1161109C (zh)	2004-08-11
CN1285189A (zh)	2001-02-28
KR19980086622A (ko)	1998-12-05
NO982197D0 (no)	1998-05-14
TWI239838B (en)	2005-09-21
BE1011925A3 (fr)	2000-03-07
JP3210288B2 (ja)	2001-09-17
RU2164405C2 (ru)	2001-03-27
HK1034902A1 (en)	2001-11-09
LU90245A1 (es)	1998-11-30
GR980100188A (el)	1999-01-29
HU9800882D0 (en)	1998-05-28
AU6904898A (en)	1998-12-03
PL326134A1 (en)	1998-12-07
ITMI980908A1 (it)	1999-10-28
SE522914C2 (sv)	2004-03-16
FR2763846A1 (fr)	1998-12-04
IL124073A (en)	2002-02-10
SG72805A1 (en)	2000-05-23
NZ330192A (en)	1999-08-30
CH693018A5 (de)	2003-01-31
MY118139A (en)	2004-09-30
TR199800937A2 (xx)	1999-10-21
BR9801989A (pt)	2000-02-08
KR100549473B1 (ko)	2006-03-23
ID20343A (id)	1998-12-03
LV12176B (lv)	1999-03-20
AU726690B2 (en)	2000-11-16
SV1998000052A (es)	1999-03-16
US5910319A (en)	1999-06-08
ZA983173B (en)	1999-10-15

Publication	Publication Date	Title
LT4477B (lt)	1999-03-25	Fluoksetino enterinės piliulės
RU2147231C1 (ru)	2000-04-10	Кишечные гранулы дульоксетина
AU1011300A (en)	2000-07-20	Opioid analgesics With Controlled Active Substance Release
US6254891B1 (en)	2001-07-03	Extended release acetaminophen
SK50442006A3 (sk)	2006-08-03	Pelety obsahujúce hydrochlorid venlafaxínu
MXPA98003636A (es)	1999-04-06	Granulos entericos de fluoxetina
IE83510B1 (en)	2004-07-14	Fluoxetine enteric pellets
HK1034902B (en)	2006-03-17	Fluoxetine enteric pellets

Legal Events

Date	Code	Title	Description
2018-05-10	MK9A	Expiry of a patent	Effective date: 20180422